Phase I clinical trials (NCT03829540, NCT04219319, NCT04162340) have now been initiated to evaluate the safety and tolerability of anti-CD4 CAR-T cells in T cell malignancies, including T cell leukemia and T cell lymphoma; the outcomes have not yet been reported. This evidence concerns the gene CD4 and T-cell non-Hodgkin lymphoma.